Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Retained Earnings: 2016-2025

Historic Retained Earnings for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to -$933.4 million.

  • UroGen Pharma's Retained Earnings fell 21.42% to -$933.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$933.4 million, marking a year-over-year decrease of 21.42%. This contributed to the annual value of -$806.2 million for FY2024, which is 18.68% down from last year.
  • UroGen Pharma's Retained Earnings amounted to -$933.4 million in Q3 2025, which was down 3.71% from -$900.0 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Retained Earnings peaked at -$382.4 million during Q1 2021, and registered a low of -$933.4 million during Q3 2025.
  • For the 3-year period, UroGen Pharma's Retained Earnings averaged around -$753.3 million, with its median value being -$745.0 million (2024).
  • Data for UroGen Pharma's Retained Earnings shows a maximum YoY slumped of 43.88% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows UroGen Pharma's Retained Earnings stood at -$467.3 million in 2021, then decreased by 23.49% to -$577.1 million in 2022, then declined by 17.72% to -$679.3 million in 2023, then declined by 18.68% to -$806.2 million in 2024, then fell by 21.42% to -$933.4 million in 2025.
  • Its Retained Earnings stands at -$933.4 million for Q3 2025, versus -$900.0 million for Q2 2025 and -$850.1 million for Q1 2025.